Company Information

  

Address: LEVEL 12, 95 PITT STREET  
City: SYDNEY, NEW SOUTH WALES 
State:  
Zip Code: 2000 
Telephone: 612 9276 1224 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

Our legal and commercial name is Prima BioMed Ltd. We were incorporated under the laws of the Commonwealth of Australia on May 21, 1987. Our registered office is located at Level 12, 95 Pitt Street, Sydney 2000 New South Wales, Australia and our telephone number is +61 (0)2 8315 7003. Our address on the Internet is www.primabiomed.com.au. The information on, or accessible through, our website is not part of this Annual Report on Form 20-F. We have included our website address in this Annual Report on Form 20-F solely as an inactive textual reference. Fiscal 2015 On 8 July 2014 Prima BioMed was granted US Patent 8,771,701 from the US patent office, covering the company's CVac cancer immunotherapy. This patent was given a term extension of almost 4 years providing for patent protection in the US for this patent until at least August 2022.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2016-30.77NAN/E

Key Financial Ratios and Statistics

FYE: 06/30

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.32Total Liab/Total Assets0.17
Net Inc/Total Assets-1.46Total Liab/Inv Cap0.18
Net Inc/Inv Cap-1.51Total Liab/Comm Equity0.04
Pretax Inc/Net Sales-35.81Interest Coverage Ratio-7706.78
Net Inc/Net Sales-35.14Curr Debt/EquityNA
Cash Flow/Net Sales-6.41LTD/Equity0.14
SG&A/NetSales30.85Total Debt/Equity0.14
Asset Utilization   Liquidity  
Net Receivables Turnover7.15Quick Ratio14.72
Inventory TurnoverNACurrent Ratio14.72
Inventory Day SalesNANet Rec/Curr Assets0.01
Net Sales/Work Cap0.09Inv/Curr AssetsNA
Net Sales/PP&E56.03  

Income Statement (Millions)

  6/30/2016 6/30/2015 6/30/2014 6/30/2013
Total Revenues(Net Sales) 1.31 1.03 1.91 1.51
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 40.54 4.40 3.86 4.44
Operating Income -45.97 -11.28 -13.64 -15.98
Interest Exp 0.01 14.12 0.00 0.00
Pretax Income -47.06 -24.82 -12.58 -13.86
Other Income -1.08 0.58 1.06 2.13
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -46.18 -24.71 -12.59 -13.94

Balance Sheet (Millions)

Assets 6/30/2016 6/30/2015 6/30/2014 6/30/2013
Cash & Short Term Investments 15.55 5.20 21.90 27.48
Receivables - Total 0.13 0.24 0.19 0.18
Inventories - Total NA NA NA NA
Total Current Assets 16.14 6.17 23.30 29.12
Net Property, Plant & Equipment 0.02 0.23 0.54 0.76
Total Assets 31.69 23.81 23.95 30.04
Liabilities        
Accounts Payable 1.10 2.21 2.62 3.23
Debt in Current Liabilities 0.00 1.16 0.00 0.03
Total Current Liabilities 1.10 3.37 2.62 3.26
Long-Term Debt 3.74 0.00 NA NA
Total Liabilities 5.39 4.84 2.63 3.26
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock NA NA NA NA
Common Stock 144.85 138.26 140.65 130.28
Retained Earnings -165.65 -123.33 -121.10 -105.23
Treasury Stock NA NA NA NA
Total Stockholders' Equity 26.30 18.98 21.32 26.77
Total Liabilities and Stockholders' Equity 31.69 23.81 23.95 30.04

Cash Flow Summary (Millions)

Categories 6/30/2016 6/30/2015 6/30/2014 6/30/2013
Net Cash Provided by Operating Activities -8.42 -5.99 -13.43 -14.68
Net Cash Provided by Investing Activities 0.08 -9.19 -1.04 11.48
Net Cash Provided by Financing Activities 19.15 8.66 6.31 6.56

Annual Summary Data (Millions)

Year Sales Net Income EPS
06/20121.56-20.44--
06/20131.51-13.94--
06/20141.91-12.59--
06/20151.03-24.71--
06/20161.31-46.18-30.77
Growth Rates-4.17----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/1791,0354.38




Report Date : 10/16/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.